Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25296239 | 0.78 | CA12 (0.46) | CA12CA2CA9LMNAALDH1A1 | |
| SCHEMBL14523329 | 0.78 | LMNA (0.42) | CA12CA2CA9LMNASMN1; SMN2 | |
| SCHEMBL7753780 | 0.76 | LMNA (0.52) | CA12CA2CA9LMNAALDH1A1 | |
| SCHEMBL31527910 | 0.75 | KDM4E (0.42) | CA12CA2CA9LMNAALDH1A1 | |
| SCHEMBL10647312 | 0.72 | LMNA (0.44) | CA12CA2CA9LMNAALDH1A1 | |
| SCHEMBL10815299 | 0.69 | HPGD (0.46) | CA12CA2CA9LMNAALDH1A1 | |
| SCHEMBL13754207 | 0.68 | LMNA (0.41) | CA12CA2CA9LMNAALDH1A1 | |
| SCHEMBL8321939 | 0.68 | LMNA (0.41) | CA12CA2CA9LMNAALDH1A1 | |
| SCHEMBL18502841 | 0.67 | CA12 (0.37) | CA12CA2CA9LMNAALDH1A1 | |
| SCHEMBL8655073 | 0.67 | LMNA (0.56) | CA12CA2CA9LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131277-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
| EP-2560963-B1 | PYRAZINE DERIVATIVES AS INHIBITORS OF THE ENZYME SCD-1 FOR THE TREATMENT OF CANCER DISEASES AND DIABETES | PF MEDICAMENT (FR) | 2016-10-05 | — | — | EP | disclosed |
| US-8962837-B2 | Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962837-B2 | Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962837-B2 | Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2013-02-14 | — | — | US | disclosed |
| US-4310551-A | Pharmacologically active substituted 1,2,4-triazines | DIAMOND SHAMROCK CORPORATION (US) | 1982-01-12 | — | — | US | disclosed |
| US-4251527-A | ANTIINFLAMMATORY AGENTS | DIAMOND SHAMROCK CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| US-4157392-A | HYPOTENSIVE AGENTS, ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS AND NERVOUS SYSTEM EFFECTS | DIAMOND SHAMROCK CORPORATION (US) | 1979-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PRMT1, NNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CA12 1487/4885CA2 1983/4885CA9 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.